Arcutis Biotherapeutics (ARQT)

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

的Arcutis Biotherapeutics, Inc. Common Stock（ARQT）股票的价格今天是，自市场开启。该公司市值为$28.91亿，日交易量为股。前一交易日收盘价为 。

您准备好开始了吗？按照以下步骤操作，或阅读我们关于在Kraken上从10美元起购买Arcutis Biotherapeutics股票的指南。